AU2018384824B2 - Cancer vaccines targeting LEMD1 and uses thereof - Google Patents

Cancer vaccines targeting LEMD1 and uses thereof Download PDF

Info

Publication number
AU2018384824B2
AU2018384824B2 AU2018384824A AU2018384824A AU2018384824B2 AU 2018384824 B2 AU2018384824 B2 AU 2018384824B2 AU 2018384824 A AU2018384824 A AU 2018384824A AU 2018384824 A AU2018384824 A AU 2018384824A AU 2018384824 B2 AU2018384824 B2 AU 2018384824B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
nucleic acid
fold
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018384824A
Other languages
English (en)
Other versions
AU2018384824A8 (en
AU2018384824A1 (en
Inventor
Neil COOCH
Bradley GARMAN
Anna SLAGER
Jian Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of AU2018384824A1 publication Critical patent/AU2018384824A1/en
Publication of AU2018384824A8 publication Critical patent/AU2018384824A8/en
Application granted granted Critical
Publication of AU2018384824B2 publication Critical patent/AU2018384824B2/en
Priority to AU2022263546A priority Critical patent/AU2022263546A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018384824A 2017-12-13 2018-12-13 Cancer vaccines targeting LEMD1 and uses thereof Active AU2018384824B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022263546A AU2022263546A1 (en) 2017-12-13 2022-11-03 Cancer vaccines targeting LEMD1 and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598329P 2017-12-13 2017-12-13
US62/598,329 2017-12-13
US201762598612P 2017-12-14 2017-12-14
US62/598,612 2017-12-14
PCT/US2018/065534 WO2019118771A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022263546A Division AU2022263546A1 (en) 2017-12-13 2022-11-03 Cancer vaccines targeting LEMD1 and uses thereof

Publications (3)

Publication Number Publication Date
AU2018384824A1 AU2018384824A1 (en) 2020-07-16
AU2018384824A8 AU2018384824A8 (en) 2020-07-30
AU2018384824B2 true AU2018384824B2 (en) 2022-08-04

Family

ID=66734873

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018384824A Active AU2018384824B2 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting LEMD1 and uses thereof
AU2022263546A Abandoned AU2022263546A1 (en) 2017-12-13 2022-11-03 Cancer vaccines targeting LEMD1 and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022263546A Abandoned AU2022263546A1 (en) 2017-12-13 2022-11-03 Cancer vaccines targeting LEMD1 and uses thereof

Country Status (11)

Country Link
US (2) US11338028B2 (https=)
EP (1) EP3724217A4 (https=)
JP (3) JP7314139B2 (https=)
KR (2) KR20240096711A (https=)
CN (1) CN111479822A (https=)
AU (2) AU2018384824B2 (https=)
BR (1) BR112020011620A2 (https=)
CA (1) CA3084137A1 (https=)
MX (2) MX2020006305A (https=)
RU (1) RU2760984C1 (https=)
WO (1) WO2019118771A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1487877B1 (en) 2001-09-18 2010-10-27 Genentech, Inc. Compositions and methods for the diagnosis of tumors
WO2004021010A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method of diagnosing colon and gastric cancers
EP1954826A4 (en) 2005-11-27 2010-05-05 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND TESTS AND METHOD FOR THEIR USE FOR DIAGNOSIS
DK2091965T3 (da) 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
KR101174452B1 (ko) * 2009-05-11 2012-08-16 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
JP2014525584A (ja) * 2011-08-31 2014-09-29 オンコサイト コーポレーション 癌の治療および診断のための方法および組成物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine
WO2017203526A1 (en) * 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GenBank Accession No. NM_001199050.2 16 February 2021 *
GenBank Accession No. NP_001185979.1 16 February 2021 *

Also Published As

Publication number Publication date
US11338028B2 (en) 2022-05-24
EP3724217A1 (en) 2020-10-21
KR20200096959A (ko) 2020-08-14
AU2018384824A8 (en) 2020-07-30
CN111479822A (zh) 2020-07-31
AU2022263546A1 (en) 2022-12-08
US20190175712A1 (en) 2019-06-13
JP2025065334A (ja) 2025-04-17
RU2760984C1 (ru) 2021-12-02
EP3724217A4 (en) 2022-01-12
CA3084137A1 (en) 2019-06-20
JP2023111915A (ja) 2023-08-10
US20220265800A1 (en) 2022-08-25
KR102673699B1 (ko) 2024-06-17
MX2024005404A (es) 2024-08-06
JP7633306B2 (ja) 2025-02-19
WO2019118771A1 (en) 2019-06-20
MX2020006305A (es) 2020-09-17
KR20240096711A (ko) 2024-06-26
BR112020011620A2 (pt) 2020-12-08
JP2021506264A (ja) 2021-02-22
JP7314139B2 (ja) 2023-07-25
AU2018384824A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
AU2017214656B2 (en) Cancer vaccines and methods of treatment using the same
US20220265801A1 (en) Cancer Vaccines Targeting PRAME and Uses Thereof
US20240358809A1 (en) Cancer vaccines targeting survivin and uses thereof
US20220265800A1 (en) Cancer vaccines targeting lemd1 and uses thereof
HK40034680A (en) Cancer vaccines targeting lemd1 and uses thereof
JP7554320B2 (ja) メソセリンを標的とするがんワクチンおよびその使用
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
KR20200140799A (ko) 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
BR112020010542A2 (pt) moléculas de ácido nucleico, vetor, composição, proteínas, usos dos anteriores, e vacinas
HK1262085A1 (en) Cancer vaccines and methods of treatment using the same
HK40034677A (en) Cancer vaccines targeting mesothelin and uses thereof
HK40044253A (en) Nucleic acid antibody constructs for use against respiratory syncytial virus

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 28 , PAGE(S) 3970 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME INOVIO PHARMACEUTICALS, INC., APPLICATION NO. 2018384824, UNDER INID (54) CORRECT THE TITLE TO READ CANCER VACCINES TARGETING LEMD1 AND USES THEREOF

FGA Letters patent sealed or granted (standard patent)